About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a global cancer company focused on the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.

PDF Corporate Presentation (August 6, 2015)

PDF Genomic Health Investor Fact Sheet (June 30, 2015)

PDF Letter to Investors (June, 27 2013)

As the field of molecular diagnostics advances and new companies offering genomic-based breast cancer tests emerge, a number of you have approached us with questions about how these efforts compare to Oncotype DX and our work at Genomic Health. We'd like to take this opportunity to highlight the important distinctions that should be taken into consideration as you evaluate these companies and their products.

View all »   RSSRecent Press Releases

Oct 7, 2015
CMS Increases Final Pricing Determination for Oncotype DX® Breast Cancer Test to Previously Established Rate of $3,416

Sep 28, 2015
Genomic Health Responds to Flawed CMS Gap-fill Pricing for Oncotype DX® Breast Cancer Test

View all »Webcasts & Presentations

Aug 4, 2015 at 4:30 PM ET
Genomic Health Second Quarter 2015 Financial Results Webcast


The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.

Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.

Contact Information

For Investors:

For Media:

Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

Shareholder Tools